Clinical Trials Logo

Gout clinical trials

View clinical trials related to Gout.

Filter by:

NCT ID: NCT06439602 Recruiting - Gout Clinical Trials

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients

Start date: June 2024
Phase: Phase 3
Study type: Interventional

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

NCT ID: NCT06414837 Not yet recruiting - Clinical trials for Gout With Hyperuricemia in Adults

Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults

Start date: June 2024
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy, and safety of HR091506 tablets for treatment of gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.

NCT ID: NCT06298071 Recruiting - Gout Clinical Trials

A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.

Start date: March 3, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs, to determine the recommended dose for phase II clinical trials, and to provide basis for formulation of administration regimen for phase II clinical trials.

NCT ID: NCT06276556 Enrolling by invitation - Gout Clinical Trials

Extension Study of ABP-671 in Participants With Gout

Start date: April 22, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).

NCT ID: NCT06258213 Recruiting - Gout Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

ABP-745
Start date: January 3, 2024
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.

NCT ID: NCT06235710 Recruiting - Clinical trials for Rheumatoid Arthritis

Prevalence of Musculoskeletal Complaints in Nursing Home Residents

Start date: January 18, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to investigate the prevalence of joint complaints in nursing home residents with and without dementia. Primary objective: Number of tender or swollen joints. Secondary objectives: 1. Only when it is possible for the nursing home resident to provide us this information: how nursing home residents themselves assess the severity of their joint complaints that day (at that time). If the nursing home resident cannot answer this question (reliably), we use the Pain Assessment Checklist for Seniors with Severe Dementia (PACSLAC-D). 2. Investigate mobility limitations among nursing home residents. 3. To understand whether an accurate (differential) diagnosis for the joint complaints is reported in the electronic files. During the study, a standard physical examination of the musculoskeletal system will performed. Nursing home residents allocated in group 1 (no dementia) also provide an answer on 3 non-incriminating questions (severity of joint complaints, pain in general and general health). Nursing home residents allocated in group 2 (dementia) answer, if possible, 1 non-incriminating question (pain in joints at that moment). These question(s) and the physical examination are also widely used in daily clinical practice. No further incriminating questions or questionnaires will be administered. If the nursing home resident cannot answer this question (reliably), we use the PACSLAC-D.

NCT ID: NCT06229145 Recruiting - Gout Clinical Trials

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Start date: January 22, 2024
Phase: Phase 4
Study type: Interventional

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to < 6 mg/dL for at least 80% of the time.

NCT ID: NCT06211322 Recruiting - Gout Clinical Trials

The Remote Monitoring of Gout Feasibility Study

ReMonit Gout
Start date: February 27, 2024
Phase: N/A
Study type: Interventional

In this feasibility trial, a digital follow-up treatment strategy with patient self-management app (Urika) and remote monitoring in specialist healthcare for patients with gout will be tested.

NCT ID: NCT06207045 Not yet recruiting - Gout Flare Clinical Trials

The Effects of Limb Elevation During Gout Flare Episodes

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of this open-label randomized controlled trial is to explore the benefit of limb elevation in inpatient gout flare episodes, compared with standard treatment The main questions are; - Is limb elevation able to reduce pain during gout flare episodes to a greater degree compared with standard treatment ? - Is Is limb elevation able to reduce joint swelling during gout flare episodes to a greater degree compared with standard treatment ? Participants will be divided into 2 group; 1. Limb elevation group 2. control group All participants will receive standard medical therapy consisting of colchicine 0.6 mg per day plus prednisolone 30 mg per day for 2 days Pain score and joint circumference will be recored at recruitment, 24 hour and 48 hour

NCT ID: NCT06189404 Completed - Gout Clinical Trials

Effect of Tigulixostat on the Pharmacokinetics of Theophylline

Start date: October 31, 2023
Phase: Phase 1
Study type: Interventional

A phase 1, open-label, drug-drug interaction study to evaluate the effect of multiple doses of tigulixostat on the pharmacokinetics of single-dose theophylline in healthy adult volunteers.